She lost 250 pounds and thought her journey was over... but then she discovered something most people don't talk about.

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Bariatric surgery is associated with a significantly greater long-term weight loss than treatment with GLP-1 receptor agonists, a new head-to-head real-world study finds.

Popular weight loss drugs such as Wegovy and Zepbound have shown incredible success in clinical trials. But in the real world ...

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, one method led to much more weight loss.

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 receptor agonists semaglutide or tirzepatide, at the end of two years, ...

People who have metabolic and bariatric surgery are significantly less likely to develop psychiatric disorders compared to ...

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 ...

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP ...